Volume 3, Issue 2, Pages (June 2017)

Slides:



Advertisements
Similar presentations
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Sleep disruption changes across the disease trajectory: Pilot findings from the healthy patterns sleep study Nancy A. Hodgson, Albert J. Safi Alzheimer's.
Application of Ultrasound and Ultrasound-Guided Intervention for Evaluating Elbow Joint Pathologies Chia-Wei Lin, Yan-Hao Chen, Wen-Shiang Chen Journal.
Volume 1, Issue 1, Pages (June 2015)
Volume 3, Issue 4, Pages (November 2017)
Volume 3, Issue 1, Pages (January 2017)
Volume 15, Issue 7, Pages (June 2016)
Volume 3, Issue 1, Pages 1-9 (January 2017)
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease  Hlin Kvartsberg, Flora.
Volume 3, Issue 2, Pages (June 2017)
Cerebrospinal fluid biomarkers for Alzheimer's disease are associated with neuropathology in cortical brain biopsy  Toni Seppälä, Ossi Nerg, Anne Koivisto,
Volume 1, Issue 3, Pages (November 2015)
Volume 3, Issue 3, Pages (September 2017)
SERUM NEUROFILAMENT LIGHT PROTEIN PREDICTS CLINICAL OUTCOME IN TRAUMATIC BRAIN INJURY  Pashtun Shahim, Magnus Gren, Victor Liman, Ulf Andreasson, Niklas.
Diabetes self-management education for adults with type 2 diabetes mellitus: A systematic review of the effect on glycemic control  Carole A. Chrvala,
Volume 1, Issue 1, Pages (June 2015)
Dement Geriatr Cogn Disord Extra 2014;4: DOI: /
Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints  Argonde C. van Harten, Pieter Jelle Visser,
Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design  Arno de Wilde, Ingrid S. van Maurik, Marleen Kunneman, Femke Bouwman, Marissa.
Corrigendum to: “Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study”
Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia  Anja Hviid Simonsen, Sanna-Kaisa Herukka, Niels Andreasen, Ines Baldeiras,
Volume 3, Pages (January 2016)
Volume 3, Issue 2, Pages (June 2017)
Alzheimer's disease drug development pipeline: 2017
An amylin analog used as a challenge test for Alzheimer's disease
Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment  Sanna-Kaisa Herukka,
Volume 2, Issue 1, Pages (January 2016)
Volume 3, Issue 1, Pages (January 2017)
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Alzheimer's disease drug development pipeline: 2018
E. Bronska, J. Kalmusova, O. Dzupova, V. Maresova, P. Kriz, J. Benes 
Biomarkers of Reflux Disease
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Dynamics of serum procalcitonin in patients after major neurosurgery
Volume 16, Issue 8, Pages (August 2017)
S. Imindu Liyanage, Clarissa Santos, Donald F. Weaver 
Mucosal Healing in Patients With Celiac Disease and Outcomes of Pregnancy: A Nationwide Population-Based Study  Benjamin Lebwohl, Olof Stephansson, Peter.
Martin R. Farlow, MD  Mayo Clinic Proceedings 
Cerebrospinal Fluid Markers of Brain Injury, Inflammation, and Blood-Brain Barrier Dysfunction in Cardiac Surgery  Björn Reinsfelt, MD, PhD, Sven-Erik.
Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain  J.-M. Aguado, C. Lumbreras, D.
Louis L. Nguyen, MD, MBA, MPH  Journal of Vascular Surgery 
Epidemiology of opportunistic infections in AIDS patients
Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study  Kumar B. Rajan, Jennifer Weuve,
Volume 91, Issue 1, Pages 1-3 (July 2016)
Y.Y. Leung, J.L. Huebner, B. Haaland, S.B.S. Wong, V.B. Kraus 
W.A. Craig  Clinical Microbiology and Infection 
Lise L. Kjaergard, Sarah L. Frederiksen, Christian Gluud 
Volume 61, Issue 4, Pages (April 2002)
Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study  Kumar B. Rajan, Jennifer Weuve,
Volume 17, Issue 2, Pages (February 1950)
Statin use and clinical outcomes among pneumonia patients
Evaluation of the inflammatory response in experimentally induced synovitis in the horse: a comparison of recombinant equine interleukin 1 beta and lipopolysaccharide 
Evaluation of diagnostic tests
News & Notes Journal of Allergy and Clinical Immunology
Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective  Matthew Baumgart, Heather M. Snyder,
A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42  Kristel Sleegers,
J. Visalakshi, L. Jeyaseelan  Clinical Epidemiology and Global Health 
Added value of 11C-PiB-PET imaging in the diagnosis of Alzheimer's disease  Kristian Frederiksen, Anne-Mette Hejl, Ian Law, Steen Hasselbalch, Gunhild.
Removing the Barriers from the Path to Eliminate Hepatitis C
Volume 53, Issue 6, Pages (June 1998)
Impact of antibiotic restrictions: the patient's perspective
DIFFERENCES IN ANALYTICAL SELECTIVITY OF β-AMYLOID (1-42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS  Hugo Marcel Vanderstichele, Emeric.
Volume 16, Issue 8, Pages (August 2017)
Volume 2, Issue 6, Pages (June 2017)
Volume 2, Issue 2, Pages (June 2016)
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.
Subcapsular Hepatic Fluid Collection Caused by Cardiac Dysfunction
Clinical Nutrition Experimental
A. Carlson, B. Bothner, R. June  Osteoarthritis and Cartilage 
Presentation transcript:

Volume 3, Issue 2, Pages 284-290 (June 2017) Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease  Camilla Steen Jensen, Erik Portelius, Peter Høgh, Lene Wermuth, Kaj Blennow, Henrik Zetterberg, Steen Gregers Hasselbalch, Anja Hviid Simonsen  Alzheimer's & Dementia: Translational Research & Clinical Interventions  Volume 3, Issue 2, Pages 284-290 (June 2017) DOI: 10.1016/j.trci.2017.03.007 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 Spaghetti plots of concentration of biomarkers in cerebrospinal fluid at baseline and at 16 weeks follow-up in outcome measures. (A) Neurofilament light (NFL), (B) neurogranin (Ng), (C) chitinase-3–like protein 1 (YKL-40), and (D) visinin-like protein-1 (VILIP-1). B: Baseline and F: 16-week follow-up. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 284-290DOI: (10.1016/j.trci.2017.03.007) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Scatterplot of relative changes from baseline to 16 weeks follow-up in outcome measure in percent. (A) Neurofilament (NFL), (B) neurogranin (Ng), (C) chitinase-3–like protein 1, and (D) visinin-like protein-1 (VILIP-1). Closed squares: controls, open circles: exercise group, and closed circles: high exercise. Displayed as mean with 95% confidential interval. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 284-290DOI: (10.1016/j.trci.2017.03.007) Copyright © 2017 The Authors Terms and Conditions